Excellence in Single Domain Biotherapeutics
Isogenica develops therapeutic VHH:
highly versatile small format antibodies which we use to construct next generation biotherapeutics for the treatment of cancer, inflammation and other serious diseases.
News & Events
Isogenica announces two Pioneering Collaborations with an Antibody Research and License Agreement, and an Asset Evaluation Deal
Isogenica, a leading innovator in VHH antibodies, is proud to unveil two significant collaborations, demonstrating the company’s commitment to advancing healthcare through cutting-edge research and development.
Not many Biotechs get to turn 25, but this month at Isogenica we are celebrating our quarter century! This edition we look back through our 25 years of new technologies, acknowledging our wonderful partnerships….
University of Leicester strikes partnership with biotech experts Isogenica to develop personalised cancer treatments
Patients could benefit from bespoke cancer-fighting treatments with fewer side effects thanks to a new partnership between a biotech company and a UK university.
Isogenica’s partnerships with global biopharmaceutical companies have resulted in a deep pipeline including one clinical Phase II asset and eleven partnered pre-clinical and discovery programs.
Isogenica works with partners through collaborative research and commercial licenses to further develop proprietary LlamdA® VHH or to discover novel LlamdA® VHH as direct therapeutics and targeting agents.
Careers at Isogenica
A career at Isogenica provides an opportunity to lead, execute or support the commercial development of next generation biotherapeutics.